Skip to Content
U.S. National Institutes of Health
Cancer Diagnosis Program Cancer Imaging Program Cancer Therapy Evaluation Program Developmental Therapeutics Program Radiation Research Program Translational Research Program Biometric Research Branch Office of Cancer Complementary and Alternative Medicine
Last Updated: 04/25/2012


Solicitation of Assays for High-Throughput Screening (HTS) to Discover Chemical Probes (R01/R21)

Program Announcements

PAR-12-058 (R01):

PAR-12-059 (R21):

Expiration dates: September 8, 2014

Contact: Suzanne Forry-Schaudies, Ph.D.

These multi-institute announcements encourage applicants to develop high-throughput screens (HTS) that are relevant to cancer. The NCI is interested in HTS intended to identify small molecules for use in elucidating molecular, cellular, or in vivo mechanisms or processes of probable or known importance to cancer biology, and for use in developing strategies for cancer prevention, diagnosis, treatment or clinical monitoring of treatment. Screens may be biochemical, cellular, or model organism-based. High-throughput screens for targets that address unmet needs in cancer prevention, treatment, or diagnosis are encouraged. Validated hits identified by HTS may be appropriate for entry in the NCI Experimental Therapeutics (NExT) Program for further development to clinical candidate status and testing in clinical trial. See for the NExT application process. Applicants may also find the NCI Developmental Therapeutics Program ( ) resources to be helpful.